Compare AbbVie Inc (ABBV) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Vanguard Value Index Fund ETF — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Vanguard Value Index Fund ETF trades at $225.17. The key difference: AbbVie Inc pays a 2.79% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | VTV | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | — |
52-Week High | $263.58 | $225.35 |
52-Week Low | $197.38 | $179.43 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
VTV trades at $224.31, up 0.42% today, with a bullish technical outlook supported by moving averages and near-term resistance at $225. The ETF has gained 22% year-to-date in 2026, outperforming growth-focused peers as value strategies attract attention amid flat market growth. A dividend of $1.08 is scheduled for June 2026.
The outlook remains positive given value's recent momentum and low exposure to tech volatility, but risks include Federal Reserve policy shifts and stretched RSI levels. Institutional activity is mixed, with some trimming positions while others increase stakes, reflecting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
